B
Bull
Bull · 25%LPAA
$10.26
シナリオ価格
$10.775
-0.034 (-0.32%)終値時点
Loading chart…
- High
- 10.775
- Open
- 10.760
- VWAP
- —
- Vol
- 0.00
- Mkt Cap
- —
- Low
- 10.775
- Amount
- 0.00
- EV/EBITDA, TTM
- 0.00
Launch One Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not selected any business combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target. It has no operations nor generated any revenues.
AI analysis of Launch One Acquisition Corp (LPAA)
holdCurrently, Launch One Acquisition Corp (LPAA) is not a strong buy. The stock is trading at $10.78 with a low RSI of 45.55, indicating it is neither overbought nor oversold. The forward P/E ratio is 0, suggesting a lack of earnings visibility, and the stock has shown minimal movement with a 5-day change of +0.05%. The main risk is the declining net income trend, which has decreased from $2,605,302 in Q3 2024 to $1,599,821 in Q2 2026.
バリュエーション指標
The current forward P/E ratio for Launch One Acquisition Corp (LPAA) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for LPAA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LPAA
イベントタイムライン
ニュース
8.501-13GlobenewswireMinovia Therapeutics Secures Two U.S. Patents Expanding Mitochondrial Therapy Technology
1.011-20GlobenewswireMinovia תציג את טכנולוגיית הגדלת מיטוכונדריה הטיפולית במצגת ובסדנה בכנס ובתערוכה השנתיים ה-67 של ASH
9.011-20GlobenewswireMinovia Therapeutics' Mitochondrial Augmentation Technology to be Highlighted in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
9.009-17GlobenewswireMinovia Therapeutics Obtains FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
9.009-17GlobenewswireMinovia Therapeutics Granted FDA Fast Track Status for MNV-201 in Treating Myelodysplastic Syndrome
LPAA FAQ — answered by Alphio AI
Launch One Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not selected any business combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target. It has no operations nor generated any revenues. It operates in the Financials sector.
Currently, Launch One Acquisition Corp (LPAA) is not a strong buy. The stock is trading at $10.78 with a low RSI of 45.55, indicating it is neither overbought nor oversold. The forward P/E ratio is 0, suggesting a lack of earnings visibility, and the stock has shown minimal movement with a 5-day change of +0.05%. The main risk is the declining net income trend, which has decreased from $2,605,302 in Q3 2024 to $1,599,821 in Q2 2026.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。